DeCure's autonomous Respiratory AI scientist is researching a drug-repurposing hypothesis for allergic rhinitis — screening already-approved drugs against its 44-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAllergic rhinitis maps to a 44-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for allergic rhinitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
protein kinase C theta (PRKCQ) — PRKCQ is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2-oxidanylidene-3~{h}-imidazo[4,5-b]pyridin-1-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5F9E · 2.0 Å · ligand 2,2-dimethyl-7-(2-oxidanylidene-3~{H}-imidazo[4,5-b]pyridin-1-yl)-1-(phenylmethyl)-3~{H}-quinazolin-4-one (5VS). Experimental structure, not a prediction.
What the evidence adds up to
A 2009 review of complementary and alternative medicine for allergic rhinitis found that few therapies have been tested in rigorous randomised, double-blind, placebo-controlled trials. The review noted that biological mechanisms and adverse effects are often poorly understood. It identified spirulina, butterbur, and phototherapy as holding some promise, but stated that complementary and alternative therapies have not been integrated into the general treatment armamentarium for allergic rhinitis.
A 1987 review of changes in treatment reported that no treatment had been shown to be clearly superior to any other. The author’s personal experience suggested intranasal topical steroids were the most effective treatment, but minor limitations made their universal use as a primary treatment questionable. Newer antihistamines were described as without significant side effects but requiring improved efficacy. Immunotherapy with recent immunological modifications of vaccines had not yet provided improved efficacy.
A 2025 review described allergic rhinitis as a chronic inflammatory disease driven by a Th2-type immune response imbalance and increased IgE production, determined by hereditary factors and environmental allergens. It stated that the involvement of cellular and molecular mediators, along with epigenetic and microbiome-related mechanisms, makes the pathogenesis complex and multifactorial. Understanding these mechanisms was described as crucial for developing effective therapeutic and preventive strategies.
What is still missing are rigorous, adequately powered randomised controlled trials for the complementary therapies that have shown some promise, and a treatment that is clearly superior to existing options. The 2025 review points to a need for therapeutic strategies that address the complex, multifactorial pathogenesis, but does not provide a specific drug or intervention that has been tested in patients.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Otolaryngology & Head & Neck Surgery · 2009 · 24 citations
Complementary and alternative medicine for allergic rhinitis
AbstractPURPOSE OF REVIEW: Otolaryngologists and other physicians who diagnose and treat allergic rhinitis encounter patients who use complementary medicine and alternative remedies. This article reviews the recent literature regarding complementary and alternative therapies for the treatment of allergic rhinitis. RECENT FINDINGS: There are a myriad of modalities for treating allergic rhinitis. Few are studied with rigorous randomized, double-blind, placebo-controlled trials for clinical efficacy. Often, the biological mechanisms and adverse effects are even less well understood. A few therapies, including spirulina, butterbur, and phototherapy hold some promise. Thus far, complementary and alternative therapies have not been integrated into the general treatment armamentarium of allergic rhinitis. SUMMARY: Several studies report beneficial effects of certain alternative treatments for allergic rhinitis. Additional insight into the mechanisms of action, short-term and long-term effects, and adverse events is needed.
American Journal of Rhinology · 1987 · 1 citations
Allergic Rhinitis: Some Recent Changes in Treatment
AbstractRecent changes in treatment of allergic rhinitis have not demonstrated a treatment that is clearly superior to any of the others. My own personal experience has suggested that intranasal topical steroids are the most effective treatment of allergic nasal disease, but minor limitations associated with this form of therapy make its universal use as a primary treatment of allergic rhinitis somewhat questionable. The newer antihistamines are without significant side effects, but require improved efficacy. This will likely occur in the near future. As for immunotherapy, recent immunological modifications of vaccines have not yet provided the clinician with improved efficacy.
Zenodo (CERN European Organization for Nuclear Research) · 2025 · 0 citations · open access
MODERN CONCEPTS OF THE ETIOLOGY AND MECHANISMS OF ALLERGIC RHINITIS
AbstractCurrent evidence indicates that allergic rhinitis is a chronic inflammatory disease primarily driven by a Th2-type immune response imbalance and increased IgE production. Its development is determined by the combined effects of hereditary factors and environmental allergens. The involvement of cellular and molecular mediators, along with epigenetic and microbiome-related mechanisms, makes the pathogenesis of allergic rhinitis complex and multifactorial. Understanding these mechanisms is crucial for the development of effective therapeutic and preventive strategies for this condition.
Çukurova medical journal (Online)/Çukurova medical journal · 2023 · 0 citations · open access
Allergic rhinitis approach in primary healthcare
AbstractAllergic rhinitis is a disease that can be seen in almost one third of societies and affect the quality of life. It has various symptoms and can also be seen combined with other diseases. Although the treatment method can vary based on the patient's characteristics, generally, avoiding the allergen, which is considered to be the source of allergy, and pharmacotherapy are sufficient. The treatment for allergic rhinitis can be performed in primary healthcare services which adopts a holistic approach. However, if the recovery of the patient cannot be achieved, they need to be directed to the otorhinolaryngology department and surgical treatment options and, if necessary, immunotherapy treatment options should be considered.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
